Can the patients with locally advanced non-small cell lung cancer (LANSCLC) tolerate 60mg/m2 docetaxel on day 1 and 30mg/m2 Cisplatin on day 1 and 2 for 2 cycles during concurrent radiotherapy (CCRT) after 2-3 cycles of induction chemotherapy?: P2-222

Rong Yu,Guangying Zhu,Anhui Shi

DOI: https://doi.org/10.1097/01.JTO.0000283930.30872.6b

IF: 20.121

2007-01-01

Journal of Thoracic Oncology

Abstract:CCRT plus consolidation chemotherapy is a standard treatment of LANSCLC. But there is still a great controversy about the chemotherapy regimen for CCRT. A group of physician in Korean found 20mg/m2 docetaxel plus 20mg/m2 cisplatin, weekly is maximum tolerated dose for patients with LANSCLC during 6 weeks of 63Gy radiotherapy. The purpose of our trial was to determine whether the NSCLC patients after 2-3 cycles of induction chemotherapy can tolerate the chemotherapy regimen of 60 mg/m2 T and 60mg/m2, 2 cycles in 6 weeks radiotherapy, based on toxicity. Previously untreated 9 patients with histological/cytologically proven Stage III non-small-cell lung cancer were eligible after induction chemotherapy for 2-3 cycles. Followed a month later by continual radiotherapy (62-70Gy in 31-35 fractions, 6-7weeks) delivered concurrently with cisplatin and docetaxel. The dosage of level 1 was of 56 mg/m2 docetaxel, on day 1 and 28mg/m2 cisplatin, on day 1 and day 2, 2 cycles during CCRT. The radiotherapy model was conformal radiotherapy or intensity modulated radiotherapy. The dosage of level 2 was 60 mg/m2 docetaxel, on day 1 and 30 mg/m2 on day 1 and day 2. Response rate was evaluated as complete remission (CR), partial remission (PR), stable disease (SD) and progressive disease (PD). Nine patients were enrolled, with median age of 58, (43-70). Seven patients were male, 2 female. The ECOG scores of 4 patients were 0, and ECOG scores of 5 patients were 1. The loss of weight of 8 patients was 0%, that of one patient was ≤5% in three months before diagnosis. Seven patients were with squamous cell carcinoma, 2 with adenocarcinoma. The objective response was as follows: PR 8/9, SD 1/9. The toxicities were showed in table 1.Table 1Nonhemotological toxicityDNFatigueLeukocyteEsopha-NauseaVomitingCoughPlateletsPneum-LPSgitisonitisGrade (NCI Toxicity criteria 3.0)123412341234123412341234234212341642411422121511--112321111_212221 Open table in a new tab The patients with LANSCLC can tolerate 60mg/m2 docetaxel and 60mg/m2 cisplatin for 2 cycles during concurrent radiotherapy after 2-3 cycles of induction chemotherapy.